An old, controversial Pfizer drug shows mid-stage efficacy against narcolepsy

Reboxetine never got much traction in the US. Marketed as an anti-depressant in Europe for the past 20 years, the Pfizer drug was provisionally FDA-approved in 1999 but the agency later retracted their permission and, more recently, a German meta-analysis made the compound a prime example of translational failure. “Ineffective and potentially harmful,” the analysis concluded.